Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO	)		Complete if Known		
				Application Number	10/560,519-Conf. #5664	
l In	VFORMATIO	N DIS	CLOSURE	Filing Date	March 20, 2006	
S	TATEMENT	BY AF	PPLICANT	First Named Inventor	Inge Dorthe Hansen	
				Art Unit	1623	
	(Use as many s	heets as ne	ecessary)	Examiner Name	M. C. Henry	
Sheet	1	of	1	Attorney Docket Number	HOI-14302/16	

	.,		U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20020035119	03-21-2002	Kumar et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	⊤⁵
	ВА	WO-00/35460	06-22-2000	Gilead Sciences, Inc.		V
	ВВ	WO-99/63970	12-16-1999	Pharmacia & Upjohn Co.		1
						Γ

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Ohara, Y. et al., Tablet for treating hyperlipidemia, comprises compression-molded formulation comprising mixture of pravastatin sodium and additive which comprises synthetic calcium silicate as a stabilizer, WPI Abstract No. 2001-613851 for JP2001233766, Aug. 28, 2001	
	СВ	Yoshimura, T., Preparation of high calcium content medicine, medical drinks, etc. containing active substance powder or extract of chrysanthemum, WPI Abstract No. 1988-215499 for JP63150227, June 22, 1988	

Cxamiler   Date	
Signature Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. \*Applicant's unique citation designation number (optional). \*Isee Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Isenter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.